Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

Phase 1/2 Completed 18 enrolled University of Minnesota American Rhinologic Society · collab

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.

Timeline

Start: 2011-02
Primary completion: 2014-09
Completion: 2014-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sodium Tetradecyl Sulfate	Unknown	3 %	Other

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

Summary

Timeline

Drugs

Indications